Literature DB >> 22622591

Detection and care of familial hypercholesterolaemia in the community: is there a role for the pharmacist?

Ines Krass1, Adrian T Walker, Gerald F Watts.   

Abstract

Familial hypercholesterolaemia (FH) is a dominantly inherited disorder present from birth that causes marked elevation in plasma cholesterol and premature coronary heart disease. It is estimated that there are at 40 million people with FH worldwide, but most remain unrecognised and inadequately treated. To bridge this gap in coronary prevention several guidelines on detecting and managing FH have been published. We briefly review these and comment on the potential role of pharmacists in case detection, point-of-care testing and pharmacotherapy.

Entities:  

Mesh:

Year:  2012        PMID: 22622591     DOI: 10.1007/s11096-012-9646-y

Source DB:  PubMed          Journal:  Int J Clin Pharm


  22 in total

Review 1.  Non-adherence to statin therapy: a major challenge for preventive cardiology.

Authors:  T R Bates; V M Connaughton; G F Watts
Journal:  Expert Opin Pharmacother       Date:  2009-12       Impact factor: 3.889

Review 2.  A systematic review of the evidence for pharmacist care of patients with dyslipidemia.

Authors:  Theresa L Charrois; Monica Zolezzi; Sheri L Koshman; Glen Pearson; Mark Makowsky; Tamara Durec; Ross T Tsuyuki
Journal:  Pharmacotherapy       Date:  2012-03       Impact factor: 4.705

Review 3.  Management of familial hypercholesterolemia in children and young adults: consensus paper developed by a panel of lipidologists, cardiologists, paediatricians, nutritionists, gastroenterologists, general practitioners and a patient organization.

Authors:  O S Descamps; S Tenoutasse; X Stephenne; I Gies; V Beauloye; M-C Lebrethon; C De Beaufort; K De Waele; A Scheen; E Rietzschel; A Mangano; J P Panier; J Ducobu; M Langlois; J-L Balligand; P Legat; V Blaton; E Muls; L Van Gaal; E Sokal; R Rooman; Y Carpentier; G De Backer; F R Heller
Journal:  Atherosclerosis       Date:  2011-06-17       Impact factor: 5.162

4.  Long-term impact of a community pharmacist intervention on cholesterol levels in patients at high risk for cardiovascular events: extended follow-up of the second study of cardiovascular risk intervention by pharmacists (SCRIP-plus).

Authors:  Carol Yamada; Jeffrey A Johnson; Patrick Robertson; Glen Pearson; Ross T Tsuyuki
Journal:  Pharmacotherapy       Date:  2005-01       Impact factor: 4.705

5.  Treatment of adults with familial hypercholesterolemia and evidence for treatment: recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia.

Authors:  Jennifer G Robinson; Anne C Goldberg
Journal:  J Clin Lipidol       Date:  2011-04-03       Impact factor: 4.766

6.  ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS).

Authors:  Zeljko Reiner; Alberico L Catapano; Guy De Backer; Ian Graham; Marja-Riitta Taskinen; Olov Wiklund; Stefan Agewall; Eduardo Alegria; M John Chapman; Paul Durrington; Serap Erdine; Julian Halcox; Richard Hobbs; John Kjekshus; Pasquale Perrone Filardi; Gabriele Riccardi; Robert F Storey; David Wood
Journal:  Eur Heart J       Date:  2011-06-28       Impact factor: 29.983

Review 7.  Guidelines for the diagnosis and management of heterozygous familial hypercholesterolemia.

Authors:  Fernando Civeira
Journal:  Atherosclerosis       Date:  2004-03       Impact factor: 5.162

Review 8.  Lipid screening and cardiovascular health in childhood.

Authors:  Stephen R Daniels; Frank R Greer
Journal:  Pediatrics       Date:  2008-07       Impact factor: 7.124

Review 9.  Mechanisms of disease: genetic causes of familial hypercholesterolemia.

Authors:  Anne K Soutar; Rossi P Naoumova
Journal:  Nat Clin Pract Cardiovasc Med       Date:  2007-04

10.  Efficacy of statins in familial hypercholesterolaemia: a long term cohort study.

Authors:  Jorie Versmissen; Daniëlla M Oosterveer; Mojgan Yazdanpanah; Joep C Defesche; Dick C G Basart; Anho H Liem; Jan Heeringa; Jacqueline C Witteman; Peter J Lansberg; John J P Kastelein; Eric J G Sijbrands
Journal:  BMJ       Date:  2008-11-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.